1. Glypican-3-targeted macrophages delivering drug-loaded exosomes offer efficient cytotherapy in mouse models of solid tumours.
- Author
-
Liu, Jinhu, Zhao, Huajun, Gao, Tong, Huang, Xinyan, Liu, Shujun, Liu, Meichen, Mu, Weiwei, Liang, Shuang, Fu, Shunli, Yuan, Shijun, Yang, Qinglin, Gu, Panpan, Li, Nan, Ma, Qingping, Liu, Jie, Zhang, Xinke, Zhang, Na, and Liu, Yongjun
- Subjects
EXTRACELLULAR vesicles ,CELLULAR recognition ,INDOLEAMINE 2,3-dioxygenase ,HEPATOCELLULAR carcinoma ,LIVER cancer - Abstract
Cytotherapy is a strategy to deliver modified cells to a diseased tissue, but targeting solid tumours remains challenging. Here we design macrophages, harbouring a surface glypican-3-targeting peptide and carrying a cargo to combat solid tumours. The anchored targeting peptide facilitates tumour cell recognition by the engineered macrophages, thus enhancing specific targeting and phagocytosis of tumour cells expressing glypican-3. These macrophages carry a cargo of the TLR7/TLR8 agonist R848 and INCB024360, a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, wrapped in C16-ceramide-fused outer membrane vesicles (OMV) of Escherichia coli origin (RILO). The OMVs facilitate internalization through caveolin-mediated endocytosis, and to maintain a suitable nanostructure, C16-ceramide induces membrane invagination and exosome generation, leading to the release of cargo-packed RILOs through exosomes. RILO-loaded macrophages exert therapeutic efficacy in mice bearing H22 hepatocellular carcinomas, which express high levels of glypican-3. Overall, we lay down the proof of principle for a cytotherapeutic strategy to target solid tumours and could complement conventional treatment. Macrophages are considered a good candidate for cancer cytotherapy because of their phagocytotic capacity, enabling them to deliver cargo to tissues. Here authors engineer macrophages that are targeted to glypican-3-expressing tumour cells and equipped with drug-loaded exosomes and show therapeutic efficiency in a mouse model of hepatocellular cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF